Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
Article in Expert Opinion on Drug Safety (May 2024)
The most recent citing publications are shown below. View all 509 publications that cite this research output on Dimensions.
Article in Expert Opinion on Drug Safety (May 2024)
Preprint in Research Square (April 2024)
Article in Frontiers in Pharmacology (March 2024)